ARHI is a maternally imprinted tumor suppressor gene whose expression is markedly downregulated in breast cancer. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. An ARHI promoter segment that spanned bases À420 to þ 58 (designated the P2 region) exhibits significantly higher promoter activity in normal cells than in cancer cells. To better understand the molecular mechanisms contributing to this differential transcriptional activity, we sought to identify transcription factors that bind to the P2 region of the ARHI promoter and regulate its activity. Sequence analysis and oligonucleotide competition in electrophoretic mobility shift assays identified an A2 fragment containing an E2F-binding site. Using specific antibodies in supershift assays, we have shown that anti-E2F1 and 4 antibodies can supershift the A2-protein complexes, whereas anti-E2F2 and 6 antibodies cannot, demonstrating that the A2 fragment interacts with specific members of the E2F family proteins. When compared with normal breast epithelial cells, breast cancer cells have significantly elevated expression of E2F1, 4 and increased E2F DNA-binding activity. Moreover, chromatin immunoprecipitation experiments revealed that both E2F1 and 4 bind to the ARHI promoter in breast cancer cells in vivo. This binding was reduced when the cells were treated with the histone deacetylase (HDAC) inhibitor -trichostatin A (TSA). When SKBr3 cells were cotransfected with an ARHI/ luciferase reporter and E2F-expression vectors, E2F1 and 4 reduced ARHI promoter activity 2-3-fold, and this reduction could be reversed by TSA treatment. The negative regulation by E2F-HDAC complexes could also be reduced by small interfering RNA of E2F1 and 4. While the retinoblastoma protein, pRB, alone had no effect on ARHI promoter activity, repression by E2F1, but not E2F4, was enhanced by the coexpression of pRB. Taken together, our results suggest that E2F1, 4 and their complexes with HDAC play an important role in downregulating the expression of the tumor suppressor gene ARHI in breast cancer cells.
ARHI is a maternally imprinted tumor suppressor gene whose expression is markedly downregulated in breast cancer. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. An ARHI promoter segment that spanned bases À420 to þ 58 (designated the P2 region) exhibits significantly higher promoter activity in normal cells than in cancer cells. To better understand the molecular mechanisms contributing to this differential transcriptional activity, we sought to identify transcription factors that bind to the P2 region of the ARHI promoter and regulate its activity. Sequence analysis and oligonucleotide competition in electrophoretic mobility shift assays identified an A2 fragment containing an E2F-binding site. Using specific antibodies in supershift assays, we have shown that anti-E2F1 and 4 antibodies can supershift the A2-protein complexes, whereas anti-E2F2 and 6 antibodies cannot, demonstrating that the A2 fragment interacts with specific members of the E2F family proteins. When compared with normal breast epithelial cells, breast cancer cells have significantly elevated expression of E2F1, 4 and increased E2F DNA-binding activity. Moreover, chromatin immunoprecipitation experiments revealed that both E2F1 and 4 bind to the ARHI promoter in breast cancer cells in vivo. This binding was reduced when the cells were treated with the histone deacetylase (HDAC) inhibitor -trichostatin A (TSA). When SKBr3 cells were cotransfected with an ARHI/ luciferase reporter and E2F-expression vectors, E2F1 and 4 reduced ARHI promoter activity 2-3-fold, and this reduction could be reversed by TSA treatment. The negative regulation by E2F-HDAC complexes could also be reduced by small interfering RNA of E2F1 and 4. While the retinoblastoma protein, pRB, alone had no effect on ARHI promoter activity, repression by E2F1, Introduction ARHI has been identified as an imprinted tumor suppressor gene whose expression is downregulated in breast and ovarian cancers (Yu et al., 1999) . ARHI encodes a small GTP-binding protein that belongs to the Ras superfamily, but that has the characteristics of a tumor suppressor gene despite 54-59% homology to the Ras proto-oncogenes. Using histochemical analysis, we found that ARHI expression was downregulated in 41% (26/64) of ductal carcinoma in situ (DCIS) lesions and in 70% (16/23) of invasive breast carcinomas when compared to the adjacent normal breast epithelium . When DCIS and invasive breast cancers were present in the same samples, ARHI was further downregulated in 26% of invasive carcinomas. Thus, there is a close association between decreased ARHI expression and progression of breast cancer . Downregulation of ARHI in breast, pancreatic and thyroid cancers has also been observed by several other groups (Lu et al., 2001; Hisatomi et al., 2002; Shi et al., 2002; Weber et al., 2005) .
ARHI is one of some 40 genes in the human genome known to be imprinted. In the case of ARHI, the maternal copy is silenced in normal cells and ARHI is expressed only from the paternal allele. Due to imprinting of the maternal allele, loss of ARHI function can be achieved with a 'single hit' during carcinogenesis (Sapienza, 1991) . Several mechanisms have been identified by which transcription of ARHI from the nonimprinted allele is downregulated. Loss of ARHI expression can occur through a genetic event, where loss of heterozygosity is observed in about 40% of breast and ovarian cancers (Peng et al., 2000) . However, downregulation of the paternal allele can also occur through epigenetic events by altering the patterns of DNA methylation, histone deacetylation and histone methylation. Our recent studies have shown that hypermethylation of the ARHI CpG island II contributes to the complete silencing of ARHI expression . Further, histone H3 deacetylation and histone H3 lysine 9 methylation have also been associated with inactivation of ARHI .
E2F consists of a small family of transcription factors that are crucial for the G1/S transition and DNA replication in mammalian cells (Cam and Dynlacht, 2003) . E2F proteins may be divided into four distinct subgroups: E2F4 and 5 often act as repressors of transcription in quiescent and early G1 cells, whereas E2F1-3 often function as activators in late G1/S phase (Cam and Dynlacht, 2003) . E2F6 and 7 are the founding members of the last two subgroups and are also considered to be transcriptional repressors. Whereas E2F6 might be the only member of its subgroup, another recently identified E2F family member (E2F8) belongs to the E2F7 subgroup (Attwooll et al., 2004) . The retinoblastoma (pRB) family of proteins is the primary negative regulator of E2F by interacting with E2F (Dyson, 1998) . No pRB family members bind to E2F while situated on the promoter, and in some cases it brings in HDAC (Attwooll et al., 2004; Bracken et al., 2004) . Recent studies have considerably expanded our understanding of the roles of E2F in transcriptional regulation of target genes during cell cycle and how it contributes to tumor formation via transcriptional activation or repression. Mu¨ller et al. (2001) have used high-density oligonucleotide arrays to identify genes in which expression changed in response to activation of E2F1-3. They showed that the E2Fs control the expression of several genes that are involved in cell proliferation. They also showed that the E2Fs regulate a number of genes involved in apoptosis, differentiation, and development. Ren et al. (2002) examined approximately 1400 proximal regions of human promoters and revealed potential E2F-binding sites at the promoters of a much larger set of cell cycle-regulated genes than initially anticipated; they also identified a remarkable cadre of genes with no previous connection to E2F regulation, including genes that encode components of the DNA damage checkpoint and repair pathways, as well as factors involved in chromatin assembly/condensation, chromosome segregation, and the mitotic spindle checkpoint. Significantly, these target genes function not only during the G1/S transition and DNA replication, but also during mitosis and at DNA damage and repair checkpoints. A number of these novel E2F targets have been shown to be repressed by the E2F4 repressor complexes (Takahashi et al., 2000) . Other studies revealed that E2F1 and 4 share overlapping functions in the activation or repression of genes (Blais et al., 2002; Gao et al., 2003; Yoshida and Inoue, 2004) . In this study, we examined the modular mechanisms that regulate ARHI gene transcription and found that E2F-HDAC complexes negatively regulate ARHI gene transcription, contributing to its inactivation in breast cancer cells.
Results
A transcriptional defect downregulates ARHI in breast cancer cells ARHI expression is dramatically reduced in all breast cancer cell lines examined and in more than 70% of invasive breast cancers . We have previously shown that the reduced ARHI expression in breast cancer cells may be attributed to at least two mechanisms: ARHI promoter hypermethylation and deletion of the ARHI gene through LOH. In addition, we have also observed a significant difference in ARHI promoter activity when an ARHI/luciferase reporter containing the region from À420 to þ 58 (designated the P2 region) was transiently transfected into normal breast epithelial cells or breast cancer cells . This region encompasses the transcription initiation site and the CpG island II, consistent with the possibility that hypermethylation, histone deacetylation and transcriptional regulation might target the same region of DNA, possibly regulating hypoacetylation and condensation of chromatin adjacent to this region.
We have designed several oligonucleotides spanning the P2 region. Gel shift assays were performed with labeled oligonucleotides and nuclear extracts prepared from breast cancer cells that do not express ARHI, and from normal breast epithelial cells that express ARHI. For one DNA element, spanning from À409 to À385 and designated A2 element, we observed a strong sequence-specific protein-DNA complex with nuclear extracts from cancer cells, but much weaker complexes with extracts from normal breast epithelial cells (Figure 1 ). Since the observed A2 fragment-binding The A2 regulatory region contains an E2F-binding site Our previous sequence analysis of the ARHI promoter identified several putative E2F-, Sp1-and AP-2-binding sites within the A2 region . To identify the transcription factor(s) that form the A2-protein complex, we synthesized four oligonucleotides with mutations that span the entire A2 element and performed competition experiments with nuclear extracts from SKBr3 cells. When used as probes, all four mutants failed to produce new bands in electrophoretic mobility shift assay (EMSA) (data not shown). While addition of wild-type (WT) A2 and mutant A2-M3 olignucleotide effectively competed for the A2-protein complex, mutant oligonucleotides A2-M1, A2-M2 and A2-M5 were unable to compete for the complex formation ( Figure 2a ). Consistent with their inability to compete for A2 binding, all three oligonucleotides share overlapping mutations within the A2 element. Furthermore, this overlapping region matched the E2F consensus-binding sequence (Tao et al., 1997) (Figure 2b ). To determine whether E2F factors are responsible for the observed A2 protein complex, WT and mutant E2F-binding oligonucleotides were used as competitors for binding to the A2 probe. As shown in Figure 2a , WT, but not mutant E2F, oligonucleotides effectively competed for A2 binding, strongly suggesting that A2 contains an E2F-binding site to which one or more members of the E2F family may bind. The E2F transcription factor family consists of eight highly related proteins with distinct functions, and by using antibodies specific for six of them we sought to identify the specific member(s) of the E2F family that bind to the A2 
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Z Lu et al fragment. Anti-E2F1, 3, 4 and 5 antibodies supershifted the A2-protein complexes, while anti-E2F2 and 6 antibodies did not ( Figure 2c ). When an E2F oligonucleotide was used as a probe in EMSA, multiple DNAprotein complexes were formed, which, as expected, could be competed by WT, but not by mutant, E2F oligonucleotides ( Figure 2d ). Importantly, A2 and A2-M3 also effectively competed E2F-DNA complexes, whereas the A2-M5 oligonucleotide (in which the E2F-binding site has been mutated) could not ( Figure 2d ). A2-M1 and A2-M2 could block part of this shift, since their E2F-binding sites are only partially altered. We also examined whether Sp1 and AP-2 might also bind to the A2 fragment, but were unable to detect any binding activity with recombinant proteins (data not shown). Taken together, our results demonstrate that the A2 fragment in the ARHI promoter contains an E2F-binding site. It has been documented that E2F transcription factors play an important role in breast cancer tumorigenesis (Zhang et al., 2000) . To examine whether the expression of E2F1 and 4 was altered in breast cancer cells, we performed Western blot and EMSA analyses using nuclear extracts from breast cancer cells and normal breast epithelial cells. Figure 3a indicates that both E2F1 and 4 are expressed at significantly higher levels in breast cancer cells than in normal breast epithelial cells. Similarly, E2F DNA-binding activities were also much higher in cancer cells (Figure 3b ).
Both E2F1 and 4 bind to the ARHI promoter, and this binding is reduced by treatment with the HDAC inhibitor trichostatin A (TSA) To investigate whether the E2Fs can bind to the ARHI promoter in intact cells, chromatin immunoprecipitation (ChIP) assays were performed using antibodies against E2F1, 2 and 4. In addition, antibodies against the known regulators of E2F: pRB, p107 and p130, were also included. Normal IgG was used as a negative control. DNA associated with the chromatin immunoprecipitated by these antibodies was then amplified by and MDA-MB-435 using antibodies against E2F1 and 4. PCR was performed with the immune complexes using primers around the A2-E2F-binding site (ARHI À524/À341) in the ARHI promoter. Lysates were run with diluent and with normal IgG as negative controls. PCR was performed with the same immune complexes using primers corresponding to a region upstream (À1145/À899) of the ARHI promoter and primers specific for human GAPDH. Detailed methods are described in Fujii et al. (2003) . (b) Negative binding of RB proteins. ChIP assays were performed with MDA-MB-435 cells using antibodies against E2F1, pRB, p107 and p130. PCR was performed using primers around the A2-E2F-binding site (À524/À341) in the ARHI promoter. (c) TSA treatment reduced E2F1 and 4 binding to the ARHI promoter. ChIP assays were performed with or without TSA treatment of MDA-MB-435 or MDA-MB-468 cells. Immunoprecipitated promoter fragments (IP) were measured using the Bioanalyzer 2100 and the DNA 500 LabChip Kit. Results are presented as a ratio of IP product to the Input product. The mean value and standard deviations for three replicate experiments are presented.
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PCR with primers specific for the A2 region of the ARHI promoter (À524/À341). As expected, no DNA fragments were detected when normal IgG or diluent was used (Figure 4a) . Similarly, ChIP assays were negative with anti-E2F2 (data not shown) and with anti-pRB, anti-p107 or anti-p130 antibodies (Figure 4b ). In contrast, DNA fragments with the expected size were detected using anti-E2F1 and 4 antibodies in breast cancer cell lines SKBr3, MDA-MB-468 and MDA-MB-435 (Figure 4a ). To further exclude nonspecific enrichment on the ARHI promoter by the anti-E2F1 and 4 antibodies, we performed ChIP assays with primers corresponding to a region upstream (À1145/À899) of the ARHI promoter, as well as primers specific for human GAPDH. As shown in Figure 4a , both primer sets did not yield any DNA products in all the three breast cancer cell lines. Our previous studies have demonstrated that treatment with the HDAC inhibitor TSA increased histone H3 acetylation in breast cancer cells. To determine whether HDAC is involved in E2F-mediated repression, we examined the effect of TSA treatment on E2F binding. We found that both E2F1-and 4-binding activities were reduced in MDA-MB-435 and MDA-MB-468 cells after treatment with TSA for 24 h (Figure 4c ). The reduced E2F-binding activity following TSA treatment is consistent with the notion that E2F and HDAC form complexes at the ARHI promoter to negatively regulate ARHI transcription.
E2F1 and 4 negatively regulate ARHI promoter activity
To functionally examine the effects of E2F family proteins on ARHI promoter activity, we cotransfected an ARHI/luciferase reporter with individual E2F Cotransfection of the ARHI/luciferase reporter with E2F1, 4-6 expression vectors reduced ARHI promoter activity by 50-80%, whereas coexpression of E2F2 or 3 had no effect or some stimulatory effects (Figure 5a ). To ensure that the inhibition of ARHI promoter by the E2F proteins was not due to nonspecific general inhibition, we cotransfected E2F1 and 4 constructs with an E2F/ luciferase reporter that contained six E2F DNA-binding sites. In agreement with earlier reports (Vigo et al., 1999) , both E2F1 and 4 greatly increased the E2F/ luciferase reporter activity (Figure 5b ). Interestingly, a DNA-binding mutant of E2F1 (E2F1-E132) also failed to inhibit the ARHI/luciferase reporter, but resulted in the derepression of the ARHI promoter (Figure 5b ). The similar inhibition of ARHI promoter activity by E2F1 and 4 was also observed in MDA-MB-435 cells (data not shown). To further confirm that the E2F repression is mediated through HDAC, SKBr3 cells were treated with 100 nM TSA for 24 h before cells were harvested for luciferase assays. As shown in Figure 5c , ARHI promoter activity was increased in TSA-treated cells when compared to cells treated with the diluent. More importantly, TSA treatment was able to reverse E2F1-and 4-mediated repression on the ARHI promoter.
Mutation of the E2F site increased ARHI promoter activity
To demonstrate that the repression by E2F1 and 4 is mediated through their binding to the ARHI promoter, we generated several independent constructs in which the E2F-binding site in the ARHI promoter was specifically mutated by site-directed mutagenesis. These constructs were then tested for their promoter activity in SKBr3 cells. Consistent with its inhibitory effect on ARHI promoter activity, mutation of the E2F-binding site resulted in a two-fold increase in ARHI promoter activity (Figure 5d ). When E2F1 and 4 expression vectors were cotransfected with the mutated ARHI/luciferase reporter, they exerted a reduced, although not completely abolished, inhibitory effect (Figure 5d ).
Knockdown of E2F1 and 4 by RNA interference partially activates ARHI expression
To further confirm the negative regulatory effects of E2F1 and 4 on ARHI expression, we used small interfering RNA (siRNA) to knockdown E2F1 and 4 expression in SKBr3 cells. At 48 h after transfection, E2F1 and 4 siRNAs effectively inhibited the expression of E2F1 and 4, respectively, but not the control b-actin (Figure 6a ). Knockdown of E2F1 and 4 protein expression individually resulted in a small, but significant, increase in ARHI expression (Po0.01). However, depletion of both E2F1 and 4 simultaneously increased the expression of ARHI by more than five-fold (Po0.01) ( Figure 6b ). As control, while the siRNA to E2F2 inhibited E2F2 expression, it had minor effect on ARHI expression. Taken together, these results strongly support the premise that both E2F1 and 4 exert negatively regulatory effects on ARHI transcription, contributing to the downregulation of ARHI expression in breast cancer cells.
pRB enhances E2F1-mediated repression of ARHI promoter
The negative results from our ChIP assays using the anti-pRB antibody suggested that pRB protein does not bind directly to the ARHI promoter. Since pRB is a known regulatory factor that controls E2F activity, we sought to examine whether E2F could still regulate ARHI promoter activity in the absence of pRB. As shown in Figure 7a , expression of neither pRB protein alone nor E2F1 protein alone in pRB-null SAOS-2 cells had any inhibitory effect on ARHI promoter activity. However, when pRB was cotransfected with E2F1 into SAOS-2 cells, or when E2F1 alone was transfected into pRB-positive SKBr3 cells, we observed a 50% reduction in ARHI promoter activity. In both cell lines, coexpression of pRB significantly enhanced the repression by E2F1, but not the repression mediated by E2F4 (Figure 7 ). Taken together, our results indicate that pRB alone has no negative effects on ARHI promoter activity; however, when expressed together, it can enhance E2F1-mediated, but not E2F4-mediated, repression of ARHI promoter. 
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Discussion
E2F plays a critical role in cell growth regulation (Cam and Dynlacht, 2003) . In quiescent cells, E2F is complexed with pRB family members and is inactive. Upon pRB phosphorylation, E2F is released and mediates activation of genes important for DNA replication and cell proliferation. From our data and those of others, it appears that E2F can also downregulate inhibitors of cell growth. Our earlier studies demonstrated that expression of ARHI leads to upregulation of p21 WAF1/CIP1 and dowregulation of cyclin D1 (Yu et al., 1999) . Consequently, downregulation of ARHI should drive cells toward proliferation. In our early report, stimulation of normal epithelial cells with growth factors known to stimulate pRB phosphorylation decreased ARHI expression (Yu et al., 1999) . E2F can also function as an oncogene. Downregulation of ARHI could be one critical mechanism by which overexpression of E2F transforms cells.
Our earlier studies demonstrated that the levels of histone H3 lysine 9/18 acetylation associated with the ARHI promoter region are significantly lower in breast cancer cells that do not express ARHI than in normal cells that express ARHI . Treatment of breast cancer cells with a CpG demethylating agent and/ or a HDAC inhibitor TSA decreased histone H3 lysine 9 methylation and increased histone H3 lysine 9/18 acetylation, and ultimately resulted in an increase in ARHI expression .
Changes in chromatin structure including histone deacetylation and H3 lysine 9 methylation that silence ARHI may be driven by two pathways: DNA methylation of CpG islands or binding of regulatory transcription factors. In breast cancer cells with hypermethylated ARHI CpG islands (such as: MDA-MB-435), ARHI expression can be increased by treating the cells with the demethylating agent 5-aza-2 0 -deoxycytidine (5-aza-dC), but not with the HDAC inhibitor TSA. However, a combination of 5-aza-dC and TSA synergistically activated ARHI expression, suggesting that, once the CpG islands are demethylated by 5-aza-dC, TSA can further increase ARHI expression by inhibiting HDAC activity. In some breast cancer cell lines (such as: SKBr3, MDA-MB-468) ARHI expression is extremely low, despite normal methylation patterns or hypomethylation of CpG island II . In these cells, the HDAC inhibitor TSA alone is sufficient to reactivate ARHI expression, suggesting that binding of specific transcription factors at the ARHI promoter regions may recruit relevant coregulators that confer histone deacetylation and/or H3 lysine 9 methylation.
To find the potential transcription factor(s), we have performed EMSA with regions of the ARHI promoter and compared their patterns between extracts from normal and cancer cells. Our studies demonstrated that the A2 segment of the ARHI promoter (bp À409 to À385) contains an E2F-binding site and binding of both E2F1 and 4 inhibited ARHI promoter activity. Our results revealed that E2F1 and 4 play similar roles in regulating the ARHI promoter. This observation is consistent with studies reported recently (Blais et al., 2002; Gao et al., 2003; Yoshida and Inoue, 2004) . In general, two distinct subgroups have been identified within the E2F family: E2F4 and 5 generally act as transcription repressors, whereas E2F1-3 function as activators (Cam and Dynlacht, 2003) . However, recent studies have highlighted that in certain settings E2F1 and 4 can exhibit similar function in transcriptional regulation. By ChIP and antibody supershift assays, Blais et al. (2002) demonstrated that E2F1 and 4 associate with the regulatory elements in the p18 INK4c promoter, in vivo as well as in vitro. Yoshida and Inoue (2004) studied the regulation of E2F on Geminin and Cdt1 expression and found that both E2F1 and 4 could activate these genes. Finally, NPAT expression has been shown to be regulated by E2F1-4 (Gao et al., 2003) . In the case of ARHI, we have found that both E2F1 and 4 can bind to the ARHI promoter and negatively regulate its activity. While E2F3 antibody could also supershift the A2-protein complexes, cotransfection of E2F3 with 
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Z Lu et al the ARHI/luciferase reporter, however, failed to affect ARHI promoter activity. This discrepancy may be due to lack of specificity of the anti-E2F3 antibody, which resulted in the nonspecific supershift. Alternatively, corepressors might exert different effects on different E2F family members. The impact of E2F5 resembled that of E2F4 in supershift and promoter assays. Since these two proteins belong to the same subfamily, their similar effects on ARHI might be anticipated. We have shown that TSA, an HDAC-specific inhibitor, can activate ARHI . Several studies have shown that E2F can repress transcription by recruiting HDAC (Rayman et al., 2002) . We examined the effect of TSA on the ability of E2F to bind to ARHI promoter. We found that binding of ARHI promoter by E2F was reduced following TSA treatment. Thus, TSA can significantly reverse the repression and activate ARHI promoter activity, suggesting that HDAC is an essential component in the E2F-mediated transcriptional regulation. Our preliminary studies to identify the critical HDAC in ARHI repression suggest that multiple HDACs are able to repress ARHI promoter activity. By ChIP assays, we also confirmed that HDAC1 and HDAC3 were found associated at the ARHI promoter regions (Feng et al., unpublished data) .
In order to understand the role of pRB protein in E2F-mediated repression, we cotransfected the ARHI/ luciferase reporter with a pRB expression vector and an E2F1 or 4 expression vector into the pRB-null cell line SAOS-2. Expression of pRB protein alone had no inhibitory effect on ARHI promoter activity; however, when expressed together with E2F1, pRB significantly enhanced the repression by E2F1 on ARHI promoter. Intriguingly, repression of ARHI by E2F4 was not affected by pRB. Brehm et al. (1998) reported that HDAC activity is physically associated with pRB. Inhibitors of HDAC interfere with the ability of pRB to repress E2F-dependent transcription. The recruitment of HDAC to E2F-regulated promoters by pRB has been proposed to repress transcription through changes in chromatin structure (Brehm et al., 1998) . Additional studies will be required to understand the interaction of these two genes.
Materials and methods
Cell lines and reagents
Human primary mammary epithelial cell lines were cultured in a 1:1 mixture of MCDB 105 and Medium 199 with 10% FBS and 10 ng/ml EGF (Sigma). Breast cancer cell lines were maintained as described previously . pRB expression vector and SAOS-2 cells were kindly provided by Drs Hongji Xu and Shixue Hu (MD Anderson Cancer Center). All E2F antibodies and normal rabbit IgG were purchased from Santa Cruz Biotechnology. They include anti-E2F-1 (sc-193x), anti-E2F-2 (sc-9967x), anti-E2F-3 (sc-879x), anti-E2F-4 (sc-866x), anti-E2F-5 (sc-1083x), anti-E2F-6 (sc-8176x) and normal rabbit IgG (sc-2027) . The E2F family expression vectors, the E2F/luciferase reporter and the E2F1 mutant E132 have been reported (Vigo et al., 1999) .
Nuclear extract preparation
Normal and cancer cells grown as monolayers were trypsinized, washed twice with PBS and pelleted. Nuclear extracts were prepared using the NE-PER Nuclear and Cytoplasmic Extraction Reagents, according to the manufacturer's instructions (Pierce). Protein concentrations were determined using BCA Protein Assay Reagents (Pierce).
Electrophoretic mobility shift assay (EMSA)
EMSA was performed with nuclear extracts from normal epithelial and cancer cell lines and 32 P end-labeled doublestranded oligonucleotide probes. The reaction mixtures were incubated at room temperature for 30 min and resolved by electrophoresis on a 6% polyacrylamide gel in 0.5 Â TBE at 41C and 80 V. After drying, the gels were autoradiographed on Hyperfilm (Amersham Biosciences) for 16-48 h with an intensifying screen at À801C. For the oligonucleotide competition experiments, nuclear extracts were incubated with 32 Plabeled probe in the presence of 200-fold molar excess of WT or mutant (mt) oligonucleotide competitors. For antibody supershift experiments, nuclear extracts were incubated with 1 mg of antibody for 1 h at 41C before addition of the radiolabeled probes. The reaction mixtures were loaded on 4% polyacrylamide gels using 0.25 Â TBE as the buffering system and run for 2.5 h at 41C and 80 V.
The oligonucleotides used are shown below with the mutated bases underlined: 
ChIP assay
The ChIP assays were performed as described previously (Chadee et al., 1999) , with minor modifications. Briefly, cells were treated with 1% formaldehyde for 8 min to crosslink proteins to DNA. After washing, the cell pellets were resuspended in 500 ml lysis buffer (150 mM NaCl, 25 mM TrisHCl (pH 7.5), 5 mM EDTA, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 0.5% deoxycholic acid) and sonicated with a Branson Sonicator 250 to yield an average DNA size of 500 bp. Sonicated extracts were subsequently clarified by centrifugation. The lysates (500 ml) were then divided into three fractions: two fractions (230 ml each) were diluted in 260 ml of lysis buffer, and the third fraction (40 ml) was used as an input control. The first lysate fraction was incubated with 5 mg of anti-E2F-1 or anti-E2F-4 antibody at 41C overnight on a 3601 rotator. The second lysate fraction was incubated with 5 mg of normal rabbit IgG or PBS as a negative control. To collect immunoprecipitated complexes, 35 ml of Sepharose G beads (Pharmacia) was added and rotated for 1 h at 41C. To elute immunoprecipitated products, 75 ml of elution buffer (50 mM Tris (pH 8.0), 1% SDS and 10 mM EDTA) was added and incubated at 651C for 2 h. The crosslinked DNA-protein complexes were reversed by heating at 651C overnight, and purified by using QiaQuick spin column. Quantitation of the DNA from the ARHI promoter regions in the immunoprecipitates was determined by PCR using gene-specific primers as described below. Individual ChIP assays were repeated at least twice to confirm the reproducibility of the PCR-based experiment. PCR amplification was performed using either immunoprecipitated DNA, a control without antibody or a 1:100 dilution of input that had not been immunoprecipitated. To assure linear amplification of DNA, pilot PCR reactions were performed initially to determine the optimal PCR conditions. In general, samples were heated at 951C for 5 min, followed by 34 cycles of 951C for 1 min, 581C for 1 min and 721C for 1 min. After cycling, samples were incubated at 721C for 7 min to permit completion of primer extension. The primer pairs used were as follows: A2-Chip-524F: 5 0 -TTTACCGGTCTTGCCACTAATG-3 0 and A2-Chip-341R1: 5 0 -TCCAAAAGCAGTTTAATGCAGG-3 0 . PCR products were electrophoresed on a 2% agarose gel, stained with ethidium bromide, and photographed. To compare the levels of amplified DNA from anti-E2F1 or anti-E2F4 immunoprecipitates, a ratio was calculated from the intensity of the PCR products in the immunoprecipitated DNA and compared to a 1:100 dilution of input DNA (total chromatin) amplified by PCR in a linear range. Semiquantitative PCR was also performed using the Bioanalyzer 2100 (Agilent Technologies, Germantown, MD) and the DNA 500 LabChip Kit (Agilent Technologies, Germantown, MD) to determine the quantity of PCR products.
ARHI/luciferase reporter constructs and transient transfection assays
Site-directed mutagenesis of the ARHI/luciferase reporter was constructed with synthetic oligonucleotide primers using the QuickChange XL site-Directed Mutagenesis Kit (Stratagene). The oligonucleotide primers had the same mutations as those used in EMSA. Mutations in the reporter constructs were confirmed by DNA sequencing. SKBr3 breast cancer cells were seeded at a density of 2 Â 10 5 /well in a six-well dish and grown to 60-70% confluence. An ARHI/luciferase reporter was cotransfected with E2F expression vectors using FuGenet 6 (Roche). After 24 h, TSA was added to cells at 200-800 mg/ml as described previously , and the cells were incubated for an additional 24 h before harvest.
Luciferase activities were determined using a Luciferase Reporter Assay System in an Analytical Luminometer Monolight 2010 (PharMingen). Protein concentrations were determined using a BCA kit (Pierce). A control vector without an insert was used as a negative control in the transfection experiments. Luciferase activities were calculated as the ratio of luciferase activity/protein concentration.
RNA interference of E2F1 and 4
The E2F1, 2 and 4 siRNA duplexes were purchased from Dharmacon Research, Inc. (Lafayette, CO). Nontarget siRNA was used as the control. SkBr3 cells were grown on 60 mm plates and transfected with siRNA, individually or in combination (final concentration, 100 nM), by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in accordance with the manufacturer's recommendations. The cells were collected 48 h after transfection. Levels of ARHI mRNA were analyzed by semiquantitative reverse transcription (RT)-PCR, which was performed using the Bioanalyzer 2100 (Agilent Technologies, Germantown, MD) and the DNA 500 Lab Chip kit (Agilent Technologies). The primers used were NY2P1: 5 0 -TCTCTCCGAGCAGCGCA-3 0 (forward primer) and 3Y2SP2: 5 0 -CGTCGCCACTCTTGCTGTGG-3 0 (reverse primer). The chips were prepared as instructed by the manufacturer. Briefly, 1 ml of each PCR product was added to the individual well of DNA 500 Chip for the reaction. Bioanalyzer read the chip and gave quantitative values for each PCR product and an electronic gel picture. Data were normalized using GAPDH as an internal control and presented as the ratio to the levels of GAPDH mRNA. Western blotting with anti-E2F1, 2, 4 and anti-b-actin was carried out to monitor their protein expression.
